Results 31 to 40 of about 142 (121)

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus [PDF]

Antimicrobial Agents and Chemotherapy, 2019
We evaluated extended-interval dosing of the investigational echinocandin rezafungin (1, 4, and 16 mg/kg on days 1, 4, and 7 postinoculation) for the treatment of disseminated invasive aspergillosis caused by azole-resistant Aspergillus fumigatus .
Nathan P. Wiederhold, Laura K. Najvar, Rosie Jaramillo, Marcos Olivo, Brian L. Wickes, Gabriel Catano, Thomas F. Patterson   +6 more
openaire   +2 more sources

Rezafungin for suppressive therapy of Candida auris in a patient with a left ventricular assist device (LVAD)

IDCases
Introduction: Invasive candidiasis is a common healthcare-associated infection with significant morbidity and mortality. Candida auris in particular has emerged as a problematic and challenging healthcare-associated infection, especially with regards to ...
Matthew A. Stack, Luis Ostrosky-Zeichner, Rodrigo Hasbun, Sun O. Park, Jessica Babic, Mona Kapadia   +5 more
doaj   +1 more source

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)

Open Forum Infectious Diseases, 2023
Abstract Background Fluconazole (FLC) resistance (R) is common in C. glabrata (CGLA). Echinocandins (ECHs) are often used as first-line therapy. R to ECHs has been associated with FKS1 and FKS2 gene alterations.
Carvalhaes, Cecilia G, Rhomberg, Paul, Klauer, Abby, Deshpande, Lalitagauri M, Castanheira, Mariana   +4 more
openaire   +1 more source

From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression

MicrobiologyOpen, Volume 15, Issue 4, August 2026.
Recent and limited evidence indicates that oral candidiasis can disseminate Candida albicans throughout the body, leading to invasive candidiasis, such as candidemia, a life‐threatening infection. Considering antifungal resistance and global outbreaks of emergent non‐albicans Candida and related yeasts, murine models help understand dissemination ...
Julia Robledo Jerez, Marcella Vieira Ambrosio, Marcela Eduarda Olegario Fernandes, Ewerton Garcia de Oliveira Mima   +3 more
wiley   +1 more source

Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method [PDF]

Clinical Microbiology and Infection, 2018
Rezafungin (CD101) is a new long-acting echinocandin allowing weekly dosing, currently undergoing phase-II clinical trials for invasive candidiasis. The aim of this study was to assess rezafungin's in vitro activity against the most frequent Candida species following the EUCAST methodology.The susceptibility of 2018 clinical Candida isolates was ...
Arendrup, M. C., Meletiadis, J., Zaragoza, O., Jørgensen, K. M., Marcos-Zambrano, L. J., Kanioura, L., Cuenca-Estrella, M., Mouton, J. W., Guinea, J.   +8 more
openaire   +4 more sources

Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials

Mycoses, Volume 69, Issue 7, July 2026.
ABSTRACT Background The efficacy and safety of rezafungin in invasive candidiasis (IC) and candidaemia was demonstrated in the Phase 2 STRIVE and Phase 3 ReSTORE trials, and an additional cohort of patients in ReSTORE from China (ReSTORE China). Objectives This post hoc analysis is the first time that combined data from all double‐blind, randomised ...
Alex Soriano, George R. Thompson III, Oliver A. Cornely, Matteo Bassetti, Bart Jan Kullberg, Patrick M. Honoré, Hervé Dupont, Jose A. Vazquez, Haihui Huang, Yingyuan Zhang, Sara Dickerson, Laura Cox, Peter G. Pappas   +12 more
wiley   +1 more source

Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria

Journal of Clinical Microbiology
This study addresses the use of other echinocandins as surrogate markers to predict the susceptibility of rezafungin against the six most common Candida spp.
Marisa L. Winkler, Lalitagauri Deshpande, John H. Kimbrough, Maura Karr, Paul Rhomberg, Abby L. Klauer, Mariana Castanheira   +6 more
doaj   +1 more source

Efficacy, Safety and Biological Characteristics of Formulation Based on Essential Oil Against Co‐Infections of Herpes Simplex Virus‐1 and Candida albicans

MicrobiologyOpen, Volume 15, Issue 1, February 2026.
Essential oils with anti‐HSV‐1 activity were identified through literature review and tested against Candida to develop a formulation for co‐infections. The blend was assessed for anti‐inflammatory properties, allergenic potential via standardized BAT, and overall antiviral efficacy.
Maura Di Vito, Domiziana Coggiatti, Marilena La Sorda, Stefania Garzoli, Giulia Lombardini, Debora Talamonti, Scilla Pizzarelli, Abdesselam Zhiri, Margherita Cacaci, Riccardo Torelli, Maurizio Sanguinetti, Francesca Bugli   +11 more
wiley   +1 more source

Activity of rezafungin against Candida auris

Journal of Antimicrobial Chemotherapy
Abstract The increasing prevalence of candidemia and invasive candidiasis infections caused by Candida auris represents a global health risk. Such infections are difficult to treat as they are often multidrug-resistant and are linked to high rates of mortality.
Jeffrey B Locke, David Andes, Shawn Flanagan, Mark Redell, Voon Ong, Jalal A Aram, Peter G Pappas, Mariana Castanheira, George R Thompson   +8 more
openaire   +2 more sources

In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China

Journal of Fungi
The efficacy of different echinocandins is assessed by evaluating the in vitro activity of a novel antifungal, rezafungin, against invasive fungal isolates in comparison with anidulafungin and caspofungin.
Simin Yang, Feifei Wan, Min Zhang, Huiping Lin, Liang Hu, Ziyi Zhou, Dongjiang Wang, Aiping Zhou, Lijun Ni, Jian Guo, Wenjuan Wu   +10 more
doaj   +1 more source